Aphrodite Health, Distinctly Focused on Women’s Mental and Physical Health
Aphrodite Health, a first-of-its-kind biotech company in the rapidly emerging multi-billion dollar psychedelic medicine sector launches today. Founded by women, and focused on addressing women’s mental and physical health with psychedelic enhanced treatments. The company has developed a two-pronged approach, with a long-term drug discovery program to bring an FDA-approved drug to market, alongside an over-the-counter consumer product slated to become available in 2022.
The company’s all-female founding team and C-Suite comprises powerhouse executives including Chief of Staff Vestaen Balbuena, who is also a Senior Associate of funding backers The Conscious Fund. Balbuena states-
“In venture capital today, less than 5% of founding teams include diverse founders. It’s important that we level the playing field so fifty percent of our portfolio includes underrepresented entrepreneurial teams. With this in mind, I am delighted to join Aphrodite Health as a co-founder and proud to be part of the team that is blazing a new trail in supporting women’s healthcare needs.”
Cannabis and psychedelics industry pioneer Olivia Mannix of Cannabrand also joins the team as co-founder and Chief Strategy Officer-
“Helping others has always been the driving force behind the work that I do. I’m thrilled to bring my extensive experience in highly regulated markets to the Aphrodite Health team and to join this leading group of female innovators focused on women’s health issues.”
COO and co-founder Victoria Armstrong, a veteran founder of multiple start-up tech companies, comments-
“There is no better team to change the way women’s health treatments than this incredible group of accomplished women and it’s wonderful to focus on something so close to my heart.”
Anne Philippi, journalist and founder of psychedelics and mental health lifestyle platform The New Health Club, has also joined the team as chairwoman. “I’m really excited to jump on board at the company’s inception.” Philippi further added-
“I love the idea of a female psychedelics biotech company working to destigmatize women’s health topics and providing much-needed targeted innovative solutions for women’s mental health.”
For further information, contact Vestaen Balbuena at info@aphrodite.health
For PR inquiries, contact Alison Voetsch at av@cannabrand.us
About Aphrodite Health
Aphrodite Health is a US-based female-focused psychedelic biotech company introducing psychedelic medicines to address women’s mental and physical health challenges overlooked by modern medicine. Launched by a team of all-female founders in 2021, the brand will launch a low-dose, targeted medicine to disrupt the existing antidepressant market used to treat hormone-related mood disorders in menopause, an overlooked health condition that will be impacting a billion women globally by 2025.
About The Conscious Fund
The Conscious Fund is the most active early-stage venture fund in the psychedelic medicine space, with a global platform-based approach to investing. Its portfolio includes leading companies in drug discovery, clinics, addiction programs, retreats, AI, technology, media and training.
Aphrodite Health, Distinctly Focused on Women’s Mental and Physical Health
Aphrodite Health, a first-of-its-kind biotech company in the rapidly emerging multi-billion dollar psychedelic medicine sector launches today. Founded by women, and focused on addressing women’s mental and physical health with psychedelic enhanced treatments. The company has developed a two-pronged approach, with a long-term drug discovery program to bring an FDA-approved drug to market, alongside an over-the-counter consumer product slated to become available in 2022.
The company’s all-female founding team and C-Suite comprises powerhouse executives including Chief of Staff Vestaen Balbuena, who is also a Senior Associate of funding backers The Conscious Fund. Balbuena states-
“In venture capital today, less than 5% of founding teams include diverse founders. It’s important that we level the playing field so fifty percent of our portfolio includes underrepresented entrepreneurial teams. With this in mind, I am delighted to join Aphrodite Health as a co-founder and proud to be part of the team that is blazing a new trail in supporting women’s healthcare needs.”
Cannabis and psychedelics industry pioneer Olivia Mannix of Cannabrand also joins the team as co-founder and Chief Strategy Officer-
“Helping others has always been the driving force behind the work that I do. I’m thrilled to bring my extensive experience in highly regulated markets to the Aphrodite Health team and to join this leading group of female innovators focused on women’s health issues.”
COO and co-founder Victoria Armstrong, a veteran founder of multiple start-up tech companies, comments-
“There is no better team to change the way women’s health treatments than this incredible group of accomplished women and it’s wonderful to focus on something so close to my heart.”
Anne Philippi, journalist and founder of psychedelics and mental health lifestyle platform The New Health Club, has also joined the team as chairwoman. “I’m really excited to jump on board at the company’s inception.” Philippi further added-
“I love the idea of a female psychedelics biotech company working to destigmatize women’s health topics and providing much-needed targeted innovative solutions for women’s mental health.”
For further information, contact Vestaen Balbuena at info@aphrodite.health
For PR inquiries, contact Alison Voetsch at av@cannabrand.us
About Aphrodite Health
Aphrodite Health is a US-based female-focused psychedelic biotech company introducing psychedelic medicines to address women’s mental and physical health challenges overlooked by modern medicine. Launched by a team of all-female founders in 2021, the brand will launch a low-dose, targeted medicine to disrupt the existing antidepressant market used to treat hormone-related mood disorders in menopause, an overlooked health condition that will be impacting a billion women globally by 2025.
About The Conscious Fund
The Conscious Fund is the most active early-stage venture fund in the psychedelic medicine space, with a global platform-based approach to investing. Its portfolio includes leading companies in drug discovery, clinics, addiction programs, retreats, AI, technology, media and training.